Navigation Links
Study shows potential benefit of dark chocolate for liver disease patients
Date:4/15/2010

Vienna, Austria, Thursday 15 April: Doctors could soon be prescribing a dose of dark chocolate to help patients suffering from liver cirrhosis and from dangerously high blood pressure in their abdomen, according to new research presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria.

According to the Spanish research, eating dark chocolate reduces damage to the blood vessels of cirrhotic patients and also lowers blood pressure in the liver. Dark chocolate contains potent anti-oxidants which reduce the post-prandial (after-meal) blood pressure in the liver (or portal hypertension) associated with damaged liver blood vessels (endothelial dysfunction). The data also showed that eating dark chocolate may exert additional beneficial effects throughout the whole body. In comparison, white chocolate, which contains no beneficial 'phytochemicals', did not result in the same effects.

Professor Mark Thursz, MD FRCP, Vice Secretary of EASL and Professor of Hepatology, at Imperial College London said: "As well as advanced technologies and high science, it is important to explore the potential of alternative sources which can contribute to the overall wellbeing of a patient. This study shows a clear association between eating dark chocolate and portal hypertension and demonstrates the potential importance of improvements in the management of cirrhotic patients, to minimise the onset and impact of end stage liver disease and its associated mortality risks".

Cirrhosis is scarring of the liver as a result of long-term, continuous damage to the liver . In cirrhosis, circulation in the liver is damaged by oxidative stress and reduced antioxidant systems. After eating, blood pressure in the abdominal veins usually increases due to increased blood flow to the liver.

This is particularly dangerous and damaging to cirrhotic patients as they already have increased blood pressure in the liver (portal hypertension) and elsewhere which, if severe, can cause blood vessel rupture. Thus, eating dark chocolate may ultimately prevent this potential threat to cirrhotic patients.

In this study 21 cirrhotic patients with end stage liver disease (child score 6.91.8;MELD 114; hepatic venous pressure gradient (HPVG*)16.63.8mmHg) were randomised to receive a standard liquid meal. Ten patients received the liquid meal containing dark chocolate (containing 85% cocoa, 0.55g of dark chocolate/Kg of body weight) while 11 patients received the liquid meal containing white chocolate which is devoid of cocoa flavonoids (anti-oxidant properties) according to body weight. HVPG, arterial pressure and portal blood flow (PBF)** were measured at baseline and 30 minutes after meal administration, using a US-Doppler.

Both meals caused a highly significant but similar increase in portal blood flow with a +24% increase in dark chocolate compared to +34% in those patients who received white chocolate. Interestingly, post-prandial hyperaemia*** was accompanied by an increase in HVPG resulting in a statistically significant increase (17.33.6mmHg to 19.12.6mmHg, p=0.07) for those patients eating dark chocolate and those receiving white chocolate (16.04.7mmHg to 19.74.1mmHg, p=0.003). Post-prandial increase in HVPG was markedly reduced in patients receiving dark chocolate (+10.316.3% Vs +26.312.7%, p=0.02).


'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Related biology technology :

1. Study shows that size affects structure of hollow nanoparticles
2. ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
3. Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study
4. New Study Shows Nu-Tek's Modified Potassium Chloride Improves Yields in Meat Processing
5. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
6. Study quantifies the electron transport effects of placing metal contacts onto graphene
7. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
8. KGI Study Reveals Diverse and Vibrant Regional Bioscience Industry
9. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
10. Memory Study Enrolling Participants Evaluating Memory Loss Vitamin
11. Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today ... Portland, Oregon -based community care ... provide population health analytics, quality reporting and care ... FamilyCare strengthen its team of quality managers, analysts ... to the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
Breaking Biology Technology:
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
Breaking Biology News(10 mins):